Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys, Genomatix, GeneGo, GenoLogics, Linguamatics, Strand Life Sciences

Premium

Accelrys Receives Non-Compliance Notice from Nasdaq…

Accelrys said last week that it had received a notice from Nasdaq stating that it is not in compliance with Nasdaq's Marketplace Rule 4310(c)(14) because it has not filed its quarterly report for its fiscal quarter ended Dec. 31, 2005.

Accelrys warned earlier this month that it would not file its quarterly report in time because it is in the process of restating its financial statements from Jan. 1, 2000, to Sept. 30, 2005, and that it expected to receive such a letter [BioInform 2-10-06].

The company said in a statement last week that it "remains in continuing discussions" with the Securities and Exchange Commission "with respect to the accounting treatment for certain of its contracts."

Accelrys said that it "cannot at this time identify the precise date when the restatement will be completed or when the company will become current in its reporting with the SEC."

Accelrys said it intends to request a hearing before the Nasdaq Listing Qualifications Panel to request the continued listing of its stock on the Nasdaq National Market while it works to regain compliance.


… and Reports $29M in New Informatics Agreements

Although it has not yet released its financial statements for the quarter ended Dec. 31, 2005, Accelrys disclosed this week that it had signed "a number of comprehensive, multi-year agreements with some of the world's largest pharmaceutical companies" during the period.

These agreements include licenses for its software and informatics tools, with durations of two to five years.

The deals represent a value of $29 million over the term of the agreements — the highest aggregate dollar value ever attributable to multi-year agreements signed in any single fiscal quarter in the company's history, Accelrys said.


KFB to Use Genomatix Software for Affy Services Offering

The Center of Excellence for Fluorescent Bioanalysis, or KFB, an authorized Affymetrix Service Provider based in Regensburg, Germany, will integrate ChipInspector, a software product from Genomatix, into its analysis pipeline, Genomatix said this week.

The combined services will be made available to KFB's customer base in industry and academia, and customers will also have "temporary access" to Genomatix' BiblioSphere PathwayEdition database of biological networks.

Financial details of the agreement were not disclosed.


J&JPRD Expands License for GeneGo's Products

GeneGo said this week that Johnson & Johnson Pharmaceutical Research & Development has added a license for its MetaBase database to an existing license for the company's MetaCore software.

Further details of the agreement were not provided.


SGUL to Use GenoLogics ProteusLIMS

GenoLogics Life Sciences Software said this week that the St. George's University of London (SGUL) Medical Biomics Center has licensed its ProteusLIMS scientific data management system.

The system will be used to integrate multiple technologies and handle data from more than 50 research teams affiliated with SGUL.

Financial details were not provided.


Roche to Pilot Linguamatics 12E for Molecular Genomic Work

Roche will pilot the Linguamatics 12E text-mining software for molecular genomics research, Linguamatics said this week.

Financial details of the deal were not released.

Linguamatics specializes in natural language processing technology and is based in Cambridge, UK.


Strand and Pharmidex to Co-Develop Blood-Brain Barrier Software

Strand Life Sciences and Pharmidex have entered into a co-marketing and -product development agreement, the companies said this week.

Under the terms of the agreement, Strand and Pharmidex will promote each other's existing products and jointly develop new software to predict the ability of compounds to cross the blood-brain barrier, the companies said.

Strand will primarily provide in silico expertise, while Pharmidex will contribute its expertise in experimental blood-brain barrier research.

Financial terms of the agreement were not disclosed.

Filed under

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.